» Articles » PMID: 20068225

Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-negative Myeloproliferative Neoplasms

Abstract

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis show an inherent tendency for transformation into leukemia (MPN-blast phase), which is hypothesized to be accompanied by acquisition of additional genomic lesions. We, therefore, examined chromosomal abnormalities by high-resolution single nucleotide polymorphism (SNP) array in 88 MPN patients, as well as 71 cases with MPN-blast phase, and correlated these findings with their clinical parameters. Frequent genomic alterations were found in MPN after leukemic transformation with up to 3-fold more genomic changes per sample compared with samples in chronic phase (P < .001). We identified commonly altered regions involved in disease progression including not only established targets (ETV6, TP53, and RUNX1) but also new candidate genes on 7q, 16q, 19p, and 21q. Moreover, trisomy 8 or amplification of 8q24 (MYC) was almost exclusively detected in JAK2V617F(-) cases with MPN-blast phase. Remarkably, copy number-neutral loss of heterozygosity (CNN-LOH) on either 7q or 9p including homozygous JAK2V617F was related to decreased survival after leukemic transformation (P = .01 and P = .016, respectively). Our high-density SNP-array analysis of MPN genomes in the chronic compared with leukemic stage identified novel target genes and provided prognostic insights associated with the evolution to leukemia.

Citing Articles

Myeloproliferative Neoplasms: Challenging Dogma.

Spivak J J Clin Med. 2024; 13(22).

PMID: 39598101 PMC: 11595126. DOI: 10.3390/jcm13226957.


Circulating CD133+/–CD34– Have Increased c- Expression in Myeloproliferative Neoplasms.

Uslu Bicak I, Tokcan B, Yavuz A, Tokdemir S Turk J Haematol. 2022; 40(1):28-36.

PMID: 36458557 PMC: 9979741. DOI: 10.4274/tjh.galenos.2022.2022.0343.


Genetic Background of Polycythemia Vera.

Regimbeau M, Mary R, Hermetet F, Girodon F Genes (Basel). 2022; 13(4).

PMID: 35456443 PMC: 9027017. DOI: 10.3390/genes13040637.


Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase.

Wang X, Rampal R, Hu C, Tripodi J, Farnoud N, Petersen B JCI Insight. 2022; 7(8).

PMID: 35259128 PMC: 9089790. DOI: 10.1172/jci.insight.156534.


Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.

Brune M, Rau A, Overkamp M, Flaadt T, Bonzheim I, Schurch C Cancers (Basel). 2021; 13(22).

PMID: 34830756 PMC: 8615857. DOI: 10.3390/cancers13225605.


References
1.
Dunbar A, Gondek L, OKeefe C, Makishima H, Rataul M, Szpurka H . 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008; 68(24):10349-57. PMC: 2668538. DOI: 10.1158/0008-5472.CAN-08-2754. View

2.
Sinclair A, Lee J, Goldstein A, Xing D, Liu S, Ju R . Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. Blood. 2001; 98(13):3658-67. DOI: 10.1182/blood.v98.13.3658. View

3.
Campbell P, Baxter E, Beer P, Scott L, Bench A, Huntly B . Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006; 108(10):3548-55. DOI: 10.1182/blood-2005-12-013748. View

4.
Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

5.
Li M, Li Z, Morris D, Rui L . Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus kinase-2 activation and insulin signaling. Endocrinology. 2007; 148(4):1615-21. PMC: 4710543. DOI: 10.1210/en.2006-1010. View